The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...

Q2 2025 Management View Helmy Eltoukhy, Co-CEO, stated that "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines, ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

Easy at-home tests for colon cancer, including FIT and Cologuard, offer alternatives to traditional colonoscopies for early ...

James Van Der Beek, whose net worth is $6 million, as per Celebrity Net Worth, has partnered with Guardant Health to raise ...

Van Der Beek is opening up about his colon cancer to increase awareness of the importance of early detection, especially as ...

Guardant Health thinks around 700,000 patients in the U.S. could eventually benefit from advanced-stage cancer screening, which would drive up sales to around $6 billion annually.